A stent is
a small tube that prevents arteries from narrowing or blocking. However, stents
are not a cure for coronary artery disease. Bio-engineered stents are an
effective way to treat a variety of vascular conditions. The current technology
in these devices is biocompatible and carries little risk of infection. This
stent type is also ideal for patients who cannot tolerate metal stents. While
bioengineered stents are becoming increasingly popular among vascular surgeons,
they are not yet available in the market. To determine the viability of
bioengineered stents, manufacturers must conduct clinical trials.
The
bio-engineered stent can be used to treat other diseases as well. For example,
the FDA has approved several stents that can reduce the risk of thrombosis.
There are several factors that drive the global bio-engineered
stent market. In addition, the development of new devices and
improved technology are improving the quality of life of patients with cardiac
and non-surgical interventions.
These
devices are made from plastic and metal and are widely used in treating blocked
arteries. As a result, they are becoming the first choice of heart patients
worldwide. There is an increasing need for better medical solutions for these
devices in many countries, including the United States and the UK. With these
advancements, bio-engineered stents have revolutionized the cardiovascular care
industry and reshaped patient lives.
The market
for bio-engineered stents is highly competitive. The growth of this market is
largely driven by the increasing prevalence of renal diseases and the growing
demand for stents to treat such diseases. In fact, cardiovascular disease is
the leading cause of death worldwide, with 17.9 million people dying each year.
It is expected to increase to 23.6 million by 2030. In the United States,
alone, cardiovascular disease accounts for 1 in 3 deaths. In September 2020,
the National Medical Products Administration (NMPA) approved OrbusNeich Medical
Co. Ltd.’s Combo Bio-Engineered Sirolimus-Eluting Stent marketing in China.